Skip to main content
  • Register
  • Help
  • Contact us

London pre-open: Stocks set to dip as investors keep an eye on Covid-19 headlines in Asia

Mon 26 April 2021 07:44 | A A A

No recommendation

No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.

Market latest

FTSE 100 | FTSE 250 | Paris CAC 40 | Dow Jones | NASDAQ

6947.99 | Negative 175.69 (2.47%)
Graph

Prices delayed by at least 15 minutes

(Sharecast News) - Stocks are expected to come under a little bit of selling pressure at the start of trading on Monday as investors monitor the headlines out of Asia concerning the epidemic.

"The slow, but steady increase in Covid-19 cases across Asia, ex-India, is weighing on sentiment in early Asian trading. India's situation dominated the weekend press, but across Japan, South Korea and Thailand and others in between, Covid-19 is undermining confidence in cyclical recovery that many, including the author, has priced into their H2 2021 outlooks," said Jeffrey Halley, Senior Market Analyst, Asia Pacific, OANDA.

"In all honesty, it is much too soon to draw conclusions on this scenario, although we will have a much better picture, I believe, in a few weeks as the situation evolves."

As of 0830 BST, futures tracking the FTSE 100 were dipping by 4.5 points to 6,895.0.

On the economic calendar for Monday, the closely-followed IFO business confidence index for Germany is scheduled for release at 0900 BST.

At 1330 BST, US durable goods orders figures for March will be published at 1330 BST.

No major economic reports are due out in the UK.

IMI ups guidance and approves share buyback plan

IMI announced a £200m share buyback and raised its guidance for annual earnings after group performance improved in the first quarter. The FTSE 250 company predicted earnings per share of between 81p an 87p a share - up from an earlier estimate of 75p to 82p. Organic revenue rose 7.7% in the three months to the end of March to £421m from a year earlier and 2.6% compared with the first quarter of 2019. IMI said based on its improving performance it would buy back £200m of shares to make the balance sheet more efficient while leaving "ample capacity" for investment and potential acquisitions.

Educational publisher Pearson reported underlying first quarter revenue growth of 5% driven by demand for global online learning. The company on Monday said its online division revenue increased 25% with strong growth in Virtual Schools due to enrolment growth in the current school year in Partner Schools as well as in US district partnerships. International sales were down 2% with a decline in English as Covid-19 continued to impact Pearson's courseware and franchise business in Latin America, despite courseware recovery in China.

AstraZeneca said on Monday that the phase 3 trial for 'nirsevimab' met its primary endpoint of a statistically significant reduction in the incidence of medically-attended lower respiratory tract infections caused by respiratory syncytial virus compared to placebo, in healthy late preterm and term infants. The FTSE 100 pharmaceutical giant also announced that 'selumetinib' had been recommended for conditional marketing authorisation in the EU for the treatment of symptomatic, inoperable plexiform neurofibromas in paediatric patients with neurofibromatosis type-1, and confirmed that 'Tagrisso', or osimertinib, had been recommended for marketing authorisation in the EU for the adjuvant treatment of adult patients with early-stage epidermal growth factor receptor-mutated non-small cell lung cancer, after complete tumour resection with curative intent.

    Daily market update emails

    • FTSE 100 riser and faller updates
    • Breaking market news, plus the latest share research, tips and broker comments

    Register now for free market updates

    The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.